Table 3 Summary of clinical trials involving PARPis
Sensitization | Study Title | Status | Intervention | Most advanced clinical phase | Setting | Trial identifier | |
|---|---|---|---|---|---|---|---|
PARPis | synergistic members | ||||||
– | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Not yet recruiting | Talazoparib | – | II | Clinical Stage III/ IV Gastric Cancer AJCC v8 | NCT04550494 |
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer | Active, not recruiting | pamiparib | – | II | Advanced or Inoperable Gastric Cancer | NCT03427814 | |
A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | Recruiting | Rucaparib | – | II | stomach cancer | NCT04171700 | |
A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer (SOLAR) | Recruiting | Olaparib | – | II | Gastric and oesophageal cancers | NCT03829345 | |
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | Recruiting | Niraparib | – | II | Gastric Cancer | NCT03840967 | |
chemotherapy | Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | Active, not recruiting | olaparib | paclitaxel | II | Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | NCT01063517 |
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | Completed | Veliparib | Carboplatin, Paclitaxel, FOLFIRI | I | Gastric Cancer | NCT02033551 | |
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NA | Fluzoparib | Apatinib, Paclitaxel | I | Recurrent and Metastatic Gastric Cancer | NCT03026881 | |
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor | Completed | Veliparib | FOLFIRI | I | Gastric Cancer | NCT01123876 | |
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer | Active, not recruiting | Olaparib | Paclitaxel | III | Gastric Cancer | NCT01924533 | |
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | BGB-290 | Temozolomide | I/II | Gastric Cancer | NCT03150810 | |
antiangiogenic agents | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | Recruiting | Olaparib | Ramucirumab | I/II | Metastatic or Locally Recurrent Gastric cancer | NCT03008278 |
ATR | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | Olaparib | ceralasertib | I/II | Gastric Cancer | NCT02264678 |
immunotherapy | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Recruiting | Rucaparib | Atezolizumab | II | Gastric or gastro-esophageal junction adenocarcinoma | NCT04276376 |
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | BGB-290 | tislelizumab | I/Ib | (HER2)-negative gastric or gastroesophageal junction cancer | NCT02660034 | |
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors (MEDIOLA) | Active, not recruiting | Olaparib | MEDI4736 | I/II | Metastatic or relapsed Gastric cancer (adenocarcinoma) | NCT02734004 | |
A Study of Niraparib Combined With MGD013 in Gastric/Gastroesophageal Junction Cancer | Recruiting | Niraparib | MGD013 | I | Gastric Cancer | NCT04178460 | |
triplet drugs | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | Recruiting | Olaparib | Paclitaxel, Pembrolizumab | II | Advanced Gastric Adenocarcinoma | NCT04209686 |
Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | Not yet recruiting | Olaparib | PIPAC, SOX | I/II | Locally-invaded-gastric Cancer | NCT04410887 | |
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME) | Recruiting | Rucaparib | Ramucirumab, Nivolumab | I/II | Advanced Gastric and Esophageal Adenocarcinoma | NCT03995017 | |